Membership
Membership and minutes for the Commission on Human Medicines (CHM) and its expert advisory groups (EAGs).
Working for us
In the public interest, ministers need the advice they receive on matters relating to the regulation of medicines and medical devices to be impartial. They also need to be able to get advice from a wide range of highly-skilled professionals who are senior and well regarded in their respective fields and from a range of appointed lay representatives.
A number of independent advisory committees have been established to provide this advice. These committees can also establish working groups to address specific problems. Members of these committees may receive a fee and can claim some expenses.
If you are interested in being part of the Commission on Human Medicines or one of its expert advisory groups you should email ECSRecruitment@mhra.gov.uk.
The Chair and Commissioners are appointed in accordance with the Code of Practice for Ministerial Appointments to Public Bodies, issued by the Commissioner for Public Appointments. The Chair and Commissioners follow a code of practice, in which they are precluded from holding personal interests. Their interests in the pharmaceutical industry are published in the Commission’s annual report each year.
The Commission meets monthly in London. The Commission is supported in its work by Expert Advisory Groups (EAGs), covering various areas of medicine. In addition, the Commission calls on experts not readily available through its membership.
Current vacancies
The CHM Expert Advisory Group is looking to appoint one expert to the Rheumatology, Immunology and Dermatology Expert Advisory Group. The closing date for applications is midday 12 April 2021.
The CHM Expert Advisory Group is looking to appoint three experts and one lay member to the Chemistry, Pharmacy and Standards Expert Advisory Group. The closing date for applications is midday 10 May 2021.
CHM Chair and Commissioners
(Chair) Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci, David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the MRC Centre for Drug Safety Science
Ms Susan Bradford Lay Representative
Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS Professor in Medical Education / Consultant Clinical Pharmacologist, University of Birmingham
Dr Jamie Fraser BSc MB ChB MRCGP GP Partner, Southside Surgery, Inverness
Professor Jonathan S Friedland MA PhD FRCP FRCPE FRCPI FESCMID FMedSci Deputy Principal, St. George’s, University of London
Professor Richard J C Gilson MD FRCP Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health & Deputy Director of the UCL Institute for Global Health
Professor Malcolm R Macleod BSc MBChB MRCP PhD FRCP (Edin): Professor of Neurology and Translational Neurosciences, University of Edinburgh and Honorary Consultant Neurologist, NHS Forth Valley
Dr Rebecca Mann BM BS FRCPCH: Consultant Paediatrician, Taunton and Somerset NHS Foundation Trust
Professor Sarah Meredith: Professor of Clinical Trials, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London
Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPath: Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals
Professor Shirley Price MSc PhD FBTS FRSB ERT FHEA FRSC MBPharmacol Soc Visiting Professor of Toxicology, University of Surrey
Professor Kevin M G Taylor BPharm PhD MRPharmS Chair of the British Pharmacopoeia Commission and Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Mrs Helen M Ward MSc, BSc (Hons), Senior Fellow HEA, RGN, RCN Nurse Practitioner, PGCEA, PG Cert NMP, Queens Nurse, Advanced Nurse Practitioner
Dr Martin Wilson MRCP (UK) MPhil (Glasgow), FRCP(Edin) Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness
Summary minutes
Summary minutes are prepared on the basis that no personal, commercial or otherwise confidential information is disclosed.
See the final summary minutes for CHM and EAGs from 2014 onwards, which you can download.
Previous minutes can be seen on the MHRA pages on the National Archives
CHM meeting dates
2021
| Jan | Feb | March | April | May | May | July | Aug | Sept | Sept/Oct | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21/22 | 18/19 | 11/12 | 8/9 | 6/7 | 27/28 | 1/2 | 5/6 | 2/3 | 30/1 | 28/29 | 25/26 | 16/17 |
Infection EAG
Remit
To advise the Commission on the safety and efficacy of medicines for use in infections including HIV, AIDS and viral hepatitis.
Chair
Professor Jonathan S Friedland MA PhD FRCP FRCPE FRCPI FESCMID FMedSci Deputy Principal, St. George’s, University of London
Members
Dr Andrew Freedman B.A M.B,B.Chir M.A M.D FRCP FRCP Reader in Infectious Diseases, Cardiff University School of Medicine/ Hon. Consultant Physician, University Hospital of Wales
Professor Richard J C Gilson MD FRCP Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection Sexual Health & Deputy Director of the UCL Institute for Global Health
Dr Richard Hobson MB BS MRCP (UK) FRCPath PhD LLM Consultant Microbiologist and Honorary Senior Lecturer, Harrogate & District NHS Foundation Trust/University of Leeds
Dr Susan Hopkins MB ChB BAO (Hons) BA FRCPI Consultant in Infectious Diseases and Microbiology, Royal Free Hampstead NHS Trust, Healthcare Epidemiologist, Health Protection Agency, Honorary Senior Lecturer, University College London
Professor Kevin Moore BSc MB BS PhD FRCP Professor of Hepatology, Royal Free Hospital, London
Dr Matthias Schmid MD FRCP DTMH Consultant Physician, Head of Department of Infection & Tropical Medicine, Director of Elective Studies Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne
Ms Hilary A Shenton CPFA Lay Representative. Retired Secretary to the School of Medicine, University of Sheffield
Cardiovascular, Diabetes, Renal, Respiratory and Allergy EAG
Remit
To advise CHM on the safety and efficacy of medicines for used for the treatment and prevention of cardiovascular, diabetes, renal, respiratory and allergy diseases.
Interim Chair
Professor Amanda Adler MD PhD FRCP
Professor of Diabetic Medicine and Health Policy, University of Oxford
Members
Dr John Firth BA BM ChB DM FRCP Consultant Physician and Nephrologist, Addenbrooke’s Hospital, Cambridge
Professor Andrew Grace MB PhD FRCP FACC FESC Honorary Professor of Experimental Cardiology, Papworth and Addenbrooke’s Hospitals Cambridge & Research Group Head, Department of Biochemistry, University of Cambridge
Professor Patrick Mark MB CHB (Hons) PhD FRCP (Glasg) Professor of Nephrology & Honorary Consultant Nephrologist, University of Glasgow and Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow
Professor Theresa McDonagh BSc (Hons), MB ChB (Hons), MD (Distinction), FRCP, FESC, FHFA Consultant Cardiologist, King’s College Hospital, London & Professor of Heart Failure King’s College, London
Dr Pallav L Shah MD MBBS FRCP Consultant Physician, Royal Brompton Hospital and Chelsea & Westminster Hospital, Reader in Respiratory Medicine, Imperial College
Professor Sarah Wild MB BChir MSc PhD FRCPE FFPH, Professor of Epidemiology, Honorary Consultant in Public Health, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh
Meeting dates
2021
| March | May | June | Sept | Nov |
|---|---|---|---|---|
| 09 | 04 | 24 | 28 | 23 |
Chemistry, Pharmacy and Standards EAG
Remit
To advise the CHM on the quality in relation to safety and efficacy of medicinal products which are the subject of marketing authorisation applications and to advise on such other matters as are referred to it.
Chair
Professor Kevin M G Taylor BPharm PhD FRPharmS Chair of the British Pharmacopoeia Commission and Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Members
Dr Majella Lane BSc PhD Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
Professor Graham Buckton BPharm PhD DSc FRPharmS FRSC Emeritus Professor of Pharmaceutics, UCL School of Pharmacy
Mr V’Iain G Fenton-May BPharm MIPharm FRPharmS Pharmaceutical Microbiologist
Professor Geoffrey W Hanlon BSc PhD MRPharmS Emeritus Professor of Pharmaceutical Microbiology, School of Pharmacy & Bio-Molecular Sciences, University of Brighton
Dr Gillian M Hawksworth MBE PhD FFRPS FRPharmS (Hon) DSc Academic Community Pharmacist, Visiting Fellow Lecturer at University of Huddersfield & Past President of the RPSGB
Mr Robert Lowe BPharmS MRPharmS Practising Hospital Pharmacist, NHS Eastern Region
Professor Christopher Marriott PhD DSc Hon DSc FRPharmS CChem FRSC FRSM (Vice Chair) Emeritus Professor of Pharmaceutics, King’s College, London
Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde.
Professor Michael D Threadgill PGCE MA PhD DSc FRSC CChem Professor Emeritus in Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Visiting Professor IBERS, Aberystwyth University
Professor Darragh Murnane PhD BSc (Pharm) PhD MRPharmS Professor of Pharmaceutics and Associate Dean (Enterprise), University of Hertfordshire
Dr Susannah Walsh BSc PhD MBA Associate Head, Leicester School of Pharmacy, Associate Professor in Microbiology De Montfort University
Professor Ben Forbes BPharm PhD Professor of Pharmaceutics, Institute of Pharmaceutical Science, Kings College London
Meeting dates
2021
| Jan | Feb | March | Apr | May | June | Aug | Aug | Sept | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 16 | 09 | 06 | 25 | 29 | 03 | 31 | 28 | 26 | 23 | 14 |
Clinical Trials, Biologicals and Vaccines EAG
Remit
To advise the CHM on:
- first time in human (FTIM) studies with new compounds acting (directly or indirectly) via the immune system with a novel target or a novel mechanism of action or having a secondary potential effect on the immune system via a mechanism of action which currently is not well characterised.
- FTIM studies with novel compounds acting via a possible or likely species specific mechanism
- Any FTIM studies which are otherwise seen as requiring expert advice
- Other clinical trials involving classes of compound where MHRA may wish to seek external expert advice or CHM may wish to have oversight
- Whether a product’s mechanism of action is novel and comes within the scope of the EAG
- Pre-meeting scientific advice documentation for within scope compounds
- Other clinical trials where MHRA may wish to seek advice or where there is a difficult risk benefit balance
- Other clinical trials involving products where a new class safety issue has been identified
- The quality, safety and efficacy of medicinal products of biological or biotechnological origin including vaccines which are the subject of marketing authorisation applications; and to advise on such other matters as are referred to it
Chair
Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPath, Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals
Members
Professor Farzin Farzaneh DPhil FRCPath FRSB, Professor of Molecular Medicine, King’s College London, Honorary Consultant in Specialist Medicine, King’s College Hospital NHS Trust
Professor Helen J Lachmann MD FRCP FRCPath (Vice Chair) Reader and Honorary Consultant in Amyloidosis and Renal Medicine, University College London
Professor Kevin Park BSc, PhD, Hon FRCP, FMedSci, FBTS, HonFBPhS Professor of Pharmacology, Department of Pharmacology, University of Liverpool
Professor Andrew Pollard PhD FRCPCH Chair of the Joint Committee on Vaccination and Immunisation; Professor of Paediatric Infection and Immunity, University of Oxford
Dr Robin Thorpe PhD FRCPath Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
Professor Marc Turner MBBS PhD MBA FRCP FRCPath FHEA Professor of Cellular Therapy; Medical Director Scottish National Blood Transfusion Service (SNBTS)
Mrs Madeleine Wang BA (Hons) Lay Representative. Patient Advocate
Meeting dates
2021
| Jan | Feb | March | Apr | May | May | June | Aug | Aug | Sept | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 | 15 | 08 | 06 | 04 | 24 | 28 | 02 | 31 | 27 | 25 | 22 | 13 |
Gastroenterology, Rheumatology, Immunology and Dermatology EAG
Remit
To advise the CHM on the safety and efficacy of medicines for use in gastroenterological, rheumatological, immunological, and dermatological diseases.
Chair
Professor Anthony G Wilson MB BCH BAO DCH PhD FRCP Professor of Rheumatology, Medical School, University of Sheffield
Members
Dr Michael Ardern-Jones BSc MBBS DPhil FRCP Associate Professor, University of Southampton and Consultant Dermatologist
Mr David Chandler Lay Representative. Chief Executive, Psoriasis and Psoriatic Arthritis Alliance, Hertfordshire
Professor Kevin Moore BSc MB BS PhD FRCP Professor of Hepatology, Royal Free Hospital, London
Professor Qasim Aziz MRCP PhD FRCP Professor of Neurogastroenterology, Director Wingate Institute of Neurogastroenterology, Centre for Neuroscience, Trauma and Surgery, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
Professor Celia Moss OBE BA(Hons) MB BS MA MRCP DM FRCP MRCPCH Consultant Dermatologist, Birmingham Women’s and Children’s NHS FT, Honorary Professor of Paediatric Dermatology, University of Birmingham
Meeting dates
| March | May | July | Sept | Dec |
|---|---|---|---|---|
| 05 | 21 | 30 | 24 | 10 |
Medicines for Women’s Health EAG
Remit
To advise the CHM on the safety and efficacy of medicines related to endocrinology and women’s reproductive health from menarche to menopause and conditions related to the menopause, such as osteoporosis. The medicines covered will include medicines for contraception, emergency contraception and termination of pregnancy; medicines for infertility and assisted conception; hormone replacement therapy (HRT) and non-hormonal treatments for osteoporosis.
Chair
Professor Philip Hannaford MB ChB DRCOG DCH MD FRCGP FFSRH FFPH, Professor of Primary Care, University of Aberdeen
Members
Ms Linda Pepper BA MA (Education), Independent Consultant: patient and public involvement in healthcare
Professor Jonathan H Tobias BA (Cantab) MBBS (London) MD (London) PhD (London) FRCP (London). Professor of Rheumatology, University of Bristol; Honorary Consultant Rheumatologist, North Bristol Trust
Dr Diana Wellesley FRCP, Head of Prenatal Genetics, Consultant and Honorary Senior Lecturer in Clinical Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton
Meeting dates
| Jan | Feb | March |
|---|---|---|
| 18 | 15 | 29 |
Neurology, Pain and Psychiatry EAG
Remit
To advise the CHM on the safety and efficacy of medicines for use in neurological conditions, pain management and psychiatric conditions.
Chair
Professor Malcolm R Macleod BSc MBChB MRCP PhD FRCP (Edin) Professor of Neurology and Translational Neurosciences, University of Edinburgh and Honorary Consultant Neurologist, NHS Forth Valley
Members
Professor Naomi Fineberg BA Hons MB BS MA MRCPsych Consultant in General Adult Psychiatry, Hertfordshire Partnership NHS
Dr David Hunt MBMS MRCP PhD Honorary Consultant Neurologist/ Wellcome Trust Clinician Scientist, Anne Rawling Regenerative Neurology Clinic, University of Edinburgh
Dr Waqar Rashid MBBS BSc MRCP(UK) PhD Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, member of the Multiple Sclerosis Society
Dr Fergus Rugg-Gunn MB BS MRCP PhD Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square, London
Dr Aditya Sharma MBBS MD MRCPsych PhD Clinical Senior Lecturer and Honorary Consultant in Child and Adolescent Psychiatry at Newcastle University and Cumbria, Northumberland Tyne and Wear NHS Foundation Trust
Dr Catherine F Stannard MB ChB FRCA FFPMRCA Consultant in Complex Pain/Pain Transformation Programme Clinical Lead, NHS Gloucestershire CCG
Professor Christopher Weir BSc (Hons) PhD MSc FRSS C.Stat Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh
Oncology and Haematology EAG
Remit
To advise the CHM on the safety, quality and efficacy of medicines used in the treatment of malignant disease or blood disorders.
Chair
Professor Poulam Patel PhD, MBBS, FRCP Professor of Clinical Oncology, University of Nottingham
Members
Professor David Bowen MA MB Bchir MD MRCP FRCPath,Consultant Haematologist, Leeds Teaching Hospitals and Honorary Professor of Myeloid Leukaemia Studies, University of Leeds
Professor Stephen Devereux PhD FRCP FRCPath Consultant Haematologist, Kings College Hospital
Dr Hugo Ford MA MB BChir MD FRCP Director of Cancer Services, Cambridge University Hospitals
Dr Robert Marcus MA FRCP FRCPath Consultant Haematologist, HCA Healthcare
Meeting dates 2021
| March | Apr | May | June | July | Aug | Sept | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|
| 25 | 29 | 20 | 24 | 29 | 26 | 23 | 21 | 18 | 09 |
Paediatric Medicines EAG
The remit of the EAG is to advise the CHM on the safety, quality and efficacy of medicines for paediatric use, including all matters relating to the implementation of the EU Paediatric Regulation.
Chair
Dr Rebecca Mann BMBS FRCPCH Consultant Paediatrician, Taunton and Somerset NHS Foundation Trust
Members
Mrs Catrin Barker, Chief Pharmacist, Pharmacy Department, Alder Hey Children’s NHS FT, Eaton Road, Liverpool
Dr Jayesh Mahendra Bhatt MBBS, MD, DCH, FRCPCH , Consultant Respiratory Paediatrician, Nottingham Childrens Hospital
Dr Helen Burdett MB ChB MRCP FRCA , Consultant Anaesthetist, Tunbridge Wells Hospital
Miss Elinor Burrows RGN RSCN MSc , Respiratory Lead Nurse & Nurse Consultant Cystic Fibrosis
Professor J Helen Cross OBE MB ChB PhD FRCP FRCPCH , The Prince of Wales’s Chair of Childhood Epilepsy, Deputy Head of Developmental Neurosciences Programme, UCL Institute of Child Health`1
Dr Daniel Hawcutt BSc (Hons), MB ChB (Hons), MD, MRCPCH , Senior Lecturer Paediatric Clinical Pharmacology, Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool
Professor Meriel Jenney MBChB MRCP MD FRCPCH , Consultant Paediatric Oncologist, Clinical Board Director, Clinical Diagnostics and Therapeutics Clinical Board, Assistant Medical Director (Cancer Services), University Hospital of Wales
Dr Kathryn Johnson MBChB FRCPCH, Consultant Neonatologist, Leeds Teaching Hospitals NHS Trust andHonorary Senior Lecturer, Leeds University
Dr Caroline Jones MB ChB FRCPCH MD, Consultant Paediatric Nephrologist, Alder Hey Children’s NHS Foundation Trust
Professor Nigel Klein BSc MBBS MRCP PhD FRCPCH, Consultant, Great Ormond Street Hospital for Children NHS Trust; Professor of Infectious Diseases and Microbiology, Institute of Child Health, UCL
Dr Rubin Minhas MB ChB MBA, GP Principal
Dr Clare Pain BMBS, MSc, MRPCH , Consultant Paediatric Rheumatologist, Clinical Lead for Rheumatology Honorary Clinical Lecturer, University of Liverpool, Co-Chair of NIHR CRN: children/Versus Arthritis Paediatric Rheumatology Clinical Studies Group and Associate Director, UK Experimental Arthritis Treatment Centre for Children (Behcet’s and scleroderma workstreams)
Ms Sara Payne BA CPE LPC , Lay Representative. Solicitor
Dr Guido Pieles PhD MD, Consultant Congenital Cardiologist, Congenital Hear Unit, Bristol Heart Institute
Professor Heather M Wallace PhD FRCPath FRSC FRS FBTS FBPhS European Registered Toxicologist ERT, Professor of Biochemical Pharmacology and Toxicology, School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen.
Dr William John Watkins BSc PhD , Senior Statistician/Lecturer, College of Biomedical & Life Sciences, Cardiff University
Dr Morris Zwi MBBCh, FRCPsych, Consultant Child & Adolescent Psychiatrist and Clinical Lead, Child & Adolescent Mental Health Services, Whittington Health, Child & Adolescent Mental Health Services
Meeting dates
2021
| Jan | Feb | March | March | Apr | May | June | July | Aug | Sept | Oct | Nov | Dec |
| 13 | 10 | 03 | 21 | 28 | 19 | 23 | 28 | 25 | 22 | 20 | 17 | 08 |
Patient and Public Engagement EAG
The Commission on Human Medicines is in the process of identifying a replacement for the previous Expert Advisory Group on Patient and Public Engagement. This will include refreshing the Group’s remit and objectives. Further details will be added to this page in due course.
Pharmacovigilance EAG
PEAG now review applications for access to Type II Yellow Card data, the completed application form should be emailed directly to pharmacovigilanceservice@mhra.gov.uk
Remit
To advise the CHM on the following in relation to human medicines including herbal products:
- the public health importance of potential new signals
- the confirmation and quantification of risks identified
- appropriate risk minimisation measures including communications
- design and progress of pharmacovigilance plans
- methodologies for pharmacovigilance.
Interim Chair
Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS Professor in Medical Education/Consultant Clinical Pharmacologist, University of Birmingham
Members
Professor Darren Ashcroft BPharm MSc PhD FRPharmS Professor of Pharmacoepidemiology, Division of Pharmacy and Optometry, Manchester University
Professor Ann Daly BA PhD FBPhS Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Dr Dan Hawcutt BSc MB ChB MD MRCPCH Senior Lecturer in Paediatric Clinical Pharmacology, Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool.
Professor Ian J Douglas BSc MSc PhD Professor of Pharmacoepidemiology, London School of Hygiene & Tropical Medicine
Dr Karen Miller BSc MBBS DRCOG DCH DFFP FRCGP GP Partner, Adelaide Medical Centre, London
Dr Rupert Payne MB ChB MRCP PhD MRCGP FRCP, Consultant Senior Lecturer in Primary Care, University of Bristol
Dr Ruben Thanacoody PGCertEd MD FRCP FRCP(Edin) Consultant Physician, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Honorary Clinical Senior Lecturer in Clinical Pharmacology, Newcastle University Honorary Consultant Clinical Toxicologist, Public Health England , Director National Poisons Information Service (Newcastle unit)
Ms Susan Hunneyball BSc (Hons) Lay Member
Dr Mark Glover BA MA MB BChir MRCP PhD Associate Professor and Honorary Consultant Physician, Clinical Pharmacology and General Medicine, University of Nottingham
Meeting dates
2021
| Jan | Feb | March | March | Apr | May | June | July | Aug | Sept | Oct | Nov | Dec |
| 14 | 11 | 03 | 31 | 28 | 20 | 24 | 29 | 25 | 23 | 21 | 18 | 09 |
Type II Yellow Card data
PEAG now review applications for access to Type II Yellow Card data, the completed application form should be emailed directly to pharmacovigilanceservice@mhra.gov.uk
Sodium Valproate Expert Working Group
Terms of reference of the Sodium Valproate expert Working Group
- To review the current risk minimisation in place and possible reasons for lack of effectiveness.
- To consider further regulatory measures required to minimize the risk of valproate use in pregnancy including, but not limited to, a contraindication for use in pregnancy in girls and women without effective contraception and a formal Pregnancy Prevention Program.
- To consider other measures required across the healthcare system to ensure compliance with regulatory position in clinical practice (e.g. shared care agreements, registries.
Chair
Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the MRC Centre for Drug Safety Science
Members
Professor J Helen Cross OBE MB ChB PhD FRCP FRCPCH The Prince of Wales’s Chair of Childhood Epilepsy, Deputy Head of Developmental Neurosciences Programme, UCL Institute of Child Health
Dr Martin Duerden B Med Sci, MB BS, DRCOG, Dip Ther, DPH, FRCGP Member of National Stakeholder Platform, Honorary Senior Research Fellow, Centre for Health Economics and Medicines Evaluation, Bangor University
Professor Jayne Lawrence Professor of Biophysical Pharmaceutics, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester University and Visiting Professor of Biophysical Pharmaceutics, Institute of Pharmaceutical Science, King’s College London
Dr John Paul Leach Honorary Associate Clinical Professor, School of Medicine, Dentistry and Nursing, University of Glasgow, Elected Member of the Association of British Neurologists (ABN)
Dr Janine Lynch BHSCT Psychiatrist, Belfast Health & Social Care Trust
Dr Rebecca Mann BMBS FRCPCH Consultant Paediatrician, Taunton and Somerset NHS Foundation Trust
Dr Karen Miller BSc MBBS DRCOG DCH DFFP FRCGP GP Partner, Adelaide Medical Centre, London
Professor Catherine Nelson-Piercy MBBSMA, FRCP, FRCOG Professor of Obstetric Medicine and Consultant Obstetric Physician, Guy’s & St Thomas’ Foundation Trust
Professor David G C Owens MD (Hons) FRCP FRCPsych Professor of Clinical Psychiatry, Edinburgh University
Ms Clare Pelham Chief Executive of the Epilepsy Society
Dr Fergus Rugg-Gunn MB BS MRCP PhD Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square, London
Professor Philip Smith Consultant Neurologist, Cardiff School of Medicine and former President of the Association of British Neurologists (ABN)
Mrs Madeleine Wang BA (Hons) Lay Representative. Patient Advocate
Invited expert
Professor Thomas R. E. Barnes MD FRCPsych DSc Professor of Clinical Psychiatry, Imperial College London
Opioids Expert Working Group
Terms of reference
The review will:
- consider the current data on the utilisation of opioid-containing medicines in the UK, both prescribed and over the counter
- examine whether the risk minimisation measures implemented for over the counter and prescription opioids have been effective or whether further measures are required
- consider the benefit/risk of opioid-containing medicines in particular for non-cancer indications, taking into account alternatives
- make recommendations for regulatory action to better support appropriate use of prescription opioids, such as relevant changes to the Summary of Product Characteristics and Patient Information Leaflets, product labelling and packaging, and any other risk minimisation measures
Chair
Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS Professor in Medical Education / Consultant Clinical Pharmacologist, University of Birmingham
Members
Dr Eileen M Baildam MB ChB DRCOG DCH RCP FRCP FRCPCH Consultant Paediatric Rheumatologist and Honorary Senior Lecturer, Alder Hey Foundation NHS Trust and University of Liverpool
Dr Helen Burdett MB ChB MRCP FRCA Consultant Anaesthetist, Tunbridge Wells Hospital
Dr Lesley Colvin Chair in Pain Medicine, University of Dundee/ Consultant in Anaesthesia & Pain Medicine, NHS Tayside, Deputy Head of Division, Population Health and Genomics, Hon. Professor in Pain Medicine, University of Edinburgh
Professor Peter Crome MD PhD DSc FRCP FFPM FBPharmacolS Emeritus Professor, Keele University, Honorary Professor, UCL
Dr Jamie Fraser BSc MB ChB MRCGP GP Partner, Southside Surgery, Inverness
Professor Philip Hannaford MB ChB DRCOG DCH MD FRCGP FFSRH FFPH Professor of Primary Care, University of Aberdeen
Dr Karen Miller BSc MBBS DRCOG DCH DFFP FRCGP GP Partner, Adelaide Medical Centre, London (Apologies)
Professor David G C Owens MD (Hons) FRCP FRCPsych Professor of Clinical Psychiatry, Edinburgh University
Dr Catherine F Stannard MB ChB FRCA FFPMRCA Consultant in Complex Pain/Pain Transformation Programme Clinical Lead, NHS Gloucestershire CCG (also sitting on PHE review board)
Professor Ash Soni OBE FFRPS FRPharmS LPN Pharmacy Chair (London); Executive & Council Member, National Association of Primary Care; English Pharmacy Board Member, Royal Pharmaceutical Society; Pharmacy Clinical Network Lead, Lambeth CCG
Mr Steve Taylor Programme Manager, PHE Alcohol, Drugs, Tobacco & Justice
Dr J P Thompson BMedSci MBChB FRCP FBTS FEAPCCT Clinical Senior Lecturer, Department of Pharmacology, Therapeutics & Toxicology, Cardiff University, and Director NPIS Cardiff Unit
Mrs Madeleine Wang BA (Hons) Lay Representative. Patient Advocate
Mrs Helen M Ward MSc, BSc (Hons), Senior Fellow HEA, RGN, RCN Nurse Practitioner, PGCEA, PG Cert NMP Queens Nurse, Advanced Nurse Practitioner
Professor Christopher Weir BSc (Hons) PhD MSc FRSS C.Stat C. Sci Personal Chair in Medical Statistics and Clinical Trials, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh
Dr Frances Williams BSc MBBS MRCP PhD CCST FRCP (Edin) Reader in Genetic Epidemiology and Hon Consultant Rheumatologist, King’s College London
Observer
Mr Steve Taylor Programme Manager, PHE Alcohol, Drugs, Tobacco & Justice
Isotretinoin Expert Working Group
Terms of reference
The terms of reference for the IEWG are:
- to evaluate information from all available sources, including relevant stakeholders (patients, patient representatives, healthcare professionals, healthcare organisations, researchers, charity and patient organisations) on psychiatric effects suspected to be associated with isotretinoin. To consider whether regulatory action is required to minimise risk and ensure awareness of the risks.
- to evaluate information from all available sources, including relevant stakeholders (patients, patient representatives, healthcare professionals, healthcare organisations, researchers, charity and patient organisations) on sexual disorders suspected to be associated with isotretinoin. To consider whether regulatory action is required to minimise risk and ensure awareness of the risks.
- to consider the impact of the available information on psychiatric effects and sexual disorders on the balance of benefits and risks of isotretinoin.
- to consider what research could be undertaken to further elucidate any risks and long-term impact of psychiatric effects and sexual disorders and inform risk minimisation measures.
- to make recommendations to the Commission on Human Medicines to improve the balance of benefits and risks for isotretinoin, to raise awareness of the associated risks and for further research to evaluate the risks.
Chair
Professor Angela Thomas OBE MB BS PhD FRCPE FRC Path
University of Edinburgh
Members
Professor Darren Ashcroft BPharm, MSc, PhD, FRPharmS Professor of Pharmacoepidemiology, Head, Drug Usage and Pharmacy Practice Group, University of Manchester
Professor Amanda Drake FRCPE Personal Chair of Epigenetics and Metabolism, Academic Director, Academic Foundation Programme, Associate Director, Edinburgh Clinical Academic Training Programme
Professor Nicol Ferrier BSc MB ChB MD FRCP FRCPsych Professor of Psychiatry and Honorary Consultant Psychiatrist, University of Newcastle
Dr Arianna Di Florio Clinical Senior Lecturer, Cardiff University Honorary Consultant Psychiatrist, Cardiff and Vale University Health Board, Adjunct Assistant Professor, University of North Carolina at Chapel Hill
Dr Clive Grattan BA MA MB BChir FRCP MD ILT Consultant Dermatologist, Norfolk and Norwich University NHS Trust
Professor David Gunnell MB ChB MRCGP PhD MSc FFPHM Professor of Epidemiology, University of Bristol
Professor Peter C Hindmarsh Professor of Paediatric Endocrinology, University College London
Dr Karen Miller BSc MBBS DRCOG DCH DFFP FRCGP
GP Partner, Adelaide Medical Centre, London
Professor Rod Mitchell Professor of Developmental Endocrinology, Honorary Consultant Paediatric Endocrinologist, UKRI Future Leaders Fellow/Academic Lead for Public Engagement MRC Centre for Reproductive Health, Queens Medical Research Institute, Edinburgh
Professor Gudrun Moore Professor of Clinical and Molecular Genetics, Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health
Mr Giangiacomo Ollandini FRCS MD Milton Keynes Hospital NHS Foundation Trust - Urology Urologist, Andrologist, MSc in andrological surgery and gender disorder
Ms Linda Pepper BA MA (Education) Independent Consultant: patient and public involvement in healthcare
Dr Amr Abdel Raheem MB BCh, MSc, DipSurg, PhD, FECSM, FEAA University College London Hospitals NHS Foundation Trust infertility & contraception, Peyronies Disease, Erectile Dysfunction and male Hypogonadism
Mrs Madeleine Wang BA (Hons) Lay Representative, Patient Advocate
Professor Allan Young Vice Dean, Academic Psychiatry (Interim), Director, Centre for Affective Disorders NIHR Senior Investigator, Academic Director, Psychological Medicine and Older Adults Clinical Academic Group, Immediate Past President of International Society for Affective Disorders, President British Association for Psychopharmacology, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London
Observers
Dr Martin Allaby Consultant Clinical Adviser, Centre for Guidelines, National Institute for Health and Care Excellence (NICE), London
Mr Graeme Kirkpatrick NHS Improvement, Head of Patient Safety
Mr Divesh Patel Deputy Regional Medicines Manager (London), Pharmacist Specialist, Care Quality Commission, Medicines Team, Primary Medical Services and Integrated Care Directorate
Dr Angelika Razzaque Executive Chair, Primary Care Dermatology Society (PCDS)
COVID-19 Therapeutics Expert Working Group
Remit
- To advise on the safety and efficacy of candidate anti-viral agents, immune-based therapies and repurposed agents for the treatment and prevention of COVID-19 infection, based on available scientific data.
- To review the robustness of the evidence of supporting agents used for the treatment of COVID-19 complications, including agents based on putative mechanisms, as currently available and based on emerging data.
- To advise on strategies and study designs to collect efficacy and safety data including novel trial designs.
- To advise on measures to minimise risks and optimise the benefit-risk balance of anti-viral agents, supportive therapies (e.g., corticosteroids, NSAIDS, chloroquine, immune modulators, etc) proposed for the treatment of COVID-19 infection and its complications.
- To advise on the benefits and risk of concomitant medications (e.g., ACE inhibitors/ AT-II blockers or immunosuppressants).
- To advise on measures to monitor safety and effectiveness of risk minimisation measures relating to these medicinal products.
- To advise the Commission on Human Medicines.
Chair
Professor Jonathan S Friedland MA PhD FRCP FRCPE FRCPI FESCMID FMedSci Deputy Principal, St. George’s, University of London
Members
Dr Kenneth Baillie MD PhD Division of Genetics and Genomics Roslin Institute, University of Edinburgh
Ms Susan Bradford Lay Representative
Professor David Dockrell MB BCh MD FRCPI FRCP (Glas) FACP Professor of Infection Medicine, University of Edinburgh
Professor Richard J C Gilson MD FRCP Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health & Deputy Director of the UCL Institute for Global Health
Sir Michael Jacobs Consultant & Hon. Senior Lecturer in Infectious Diseases Royal Free London NHS Foundation Trust
Professor Nigel Klein BSc MBBS MRCP PhD FRCPCH Consultant, Great Ormond Street Hospital for Children NHS Trust; Professor of Infectious Diseases and Microbiology, Institute of Child Health, UCL
Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPath - Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals
Professor B Kevin Park BSc PhD FMedSci HonFRCP FBTS HonFBPhs Professor of Pharmacology, University of Liverpool
Professor Deenan Pillay Professor of Virology, UCL Pro-Vice-Provost International
Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the MRC Centre for Drug Safety Science
Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA ,FRSC, MBPharmacolSoc Emerita Professor of Toxicology, University of Surrey Visiting Profesor of Toxicology, University of Hertfordshire
Observers
Professor Stuart Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon) Professor of Rheumatology, University of Edinburgh, Western General Hospital, Edinburgh
Department of Health & Social Care
Public Health England
NHS England & NHS Improvement
National Institute for Health and Care Excellence (NICE)
COVID-19 Vaccines Safety Surveillance Methodologies Expert Working Group
Remit
Pre-deployment phase
- To landscape the different healthcare datasets that are currently available in the UK to capture near real-time information on COVID-19 vaccine exposure and study endpoints relevant to vaccine safety and potential for disease enhancement (and effectiveness). This should take into account a range of potential scenarios for vaccine deployment (i.e. the point of administration and any prioritised/targeted immunisation), and should advise on the need for further data capture and linkage.
- To advise on the most suitable study endpoints and design(s) to monitor COVID-19 vaccine safety, and potential for disease enhancement (and effectiveness).
- To support engagement with UK institutions who may be planning/in a position to conduct COVID-19 vaccine safety studies. This is to encourage and facilitate studies that are complementary in terms of objective and design, to avoid duplication and to accommodate a suitable range of study endpoints and scenarios for vaccine deployment.
- To advise on proposals for enhanced passive surveillance.
- To advise on communications in support of the pharmacovigilance strategy.
Post-deployment phase
- To advise on the emerging evidence from all data sources on the risks and benefits of vaccine(s) during the course of any COVID-19 immunisation campaign in the UK. This includes measures to minimise risks, and optimise the benefit-risk balance for individual vaccines, such as any new precautions or restrictions on use.
- To advise on any communications to health professionals and the public.
- To advise on measures to monitor impact/effectiveness of any additional risk minimisation.
Chair
Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPath Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals & Chair of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG) & Member of the Commission on Human Medicines (CHM)
Members
Professor Ian J Douglas BSc MSc PhD Senior Lecturer in Pharmacoepidemiology, London School of Hygiene & Tropical Medicine & Member of the Pharmacovigilance Expert Advisory Group (PEAG)
Professor Jonathan S Friedland MA PhD FRCP FRCPE FRCPI FESCMID FMedSci Deputy Principal, St. George’s, University of London & Chair of the Infections Expert Advisory Group (IEAG) & Member of the Commission on Human Medicines (CHM)
Sir Michael Jacobs MA PhD MB BS FRCP FRCP Edin DTM&H Clinical Director of Infection, Royal Free London NHS Foundation Trust & Hon. Senior Lecturer, Liverpool School of Tropical Medicine
Professor Simon De Lusignan Professor of Primary Care and Clinical Informatics, University of Oxford
Dr Rupert Payne PhD MRCGP FRCPE FBPhS Consultant Senior Lecturer in Primary Care, University of Bristol & Member of the Pharmacovigilance Expert Advisory Group (PEAG)
Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the MRC Centre for Drug Safety Science
Professor Siobhan Quenby MBBS BSc MD FRCOG Professor of Obstetrics, Warwick University & Member of the Medicines for Women’s Health Expert Advisory Group (MWHEAG)
Professor Chris Robertson PhD MSc BSc Professor of Public Health Epidemiology, University of Strathclyde
Professor Calum Semple PhD FRCPCH FRCPE FHEA Professor of Outbreak Medicine University of Liverpool
Invited Experts
Professor Elizabeth Miller Department of Infectious Disease Epidemiology, Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine
Professor Anthony Scott JCVI member, and Professor of vaccine epidemiology, Director HPRU in immunisation
Helen McDonald LSHTM Health Protection Research Unit
Jemma Walker LSHTM Health Protection Research Unit
Observers
Professor Liam Smeeth MBChB FRCGP FRCP MSc PhD FMedSci Professor of Clinical Epidemiology, London School of Hygiene & Tropical Medicine (LSHTM) & MHRA, Non-Executive Director (Board)
Visiting Experts
Professor Andrew Pollard FRCPCH PhD FMedSci Chief Investigator of the Oxford ChAD vaccine
Professor of Paediatric Infection and Immunity, Director of Graduate Studies, Department of Paediatrics, Vice Master, St Cross College, University of Oxford & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Professor Robin Shattock Lead Scientist for the Imperial saRNA vaccine programme
Professor Sheena McCormack Clinical Project Lead at MRC CTU at UCL
COVID-19 Vaccines Benefit Risk Expert Working Group
Remit
- To advise CHM on the quality, safety and efficacy of COVID-19 vaccines and on the balance of benefit and risks prior to authorisation.
- To coordinate safety evaluation with the Clinical Trials, Biologicals and Vaccines Expert Advisory Group.
- To report its conclusions and recommendations to the Commission on Human Medicines.
- To advise on the emerging evidence from all data sources on the risks and benefits of vaccine(s) during the course of any COVID-19 immunisation campaign in the UK. This includes measures to minimise risks, and optimise the benefit-risk balance for individual vaccines, such as any new precautions or restrictions on use.
- To advise on any communications to health professionals and the public.
- To advise on measures to monitor impact/effectiveness of any additional risk minimisation.
Chair
Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the MRC Centre for Drug Safety Science
Members
Professor Judith Breuer MD FRCPath FmedSci Professor of Virology, University College London (UCL), Division of Infection and Immunity, London
Professor Gordon Dougan FRS Department of Medicine, Cambridge Infectious Diseases, University of Cambridge
Professor Neil French MB ChB FRCP PhD Head Department of Clinical Infection Microbiology and Immunology, Chair of Infectious Diseases & Global Health, Hon Consultant Infectious Diseases, Royal Liverpool & Broadgreen University Hospitals Trust
Professor David Goldblatt MB ChB FRCPCH FRCP PhD Professor of Vaccinology and Immunology, Consultant in Paediatric Immunology, NIHR Senior Investigator, Great Ormond Street Hospital & University College London
Ms Susan Hunneyball BSc Lay Member, Member of the Pharmacovigilance Expert Advisory Group (PEAG) and Advisory Board on the Registration of Homeopathic Products (ABRHP)
Professor Kimme Hyrich MD PhD FRCPC Professor of Epidemiology and Honorary Consultant in Rheumatology, Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, University of Manchester and Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust
Sir Michael Jacobs MA PhD MB BS FRCP FRCP Edin DTM&H Clinical Director of Infection, Royal Free London NHS Foundation Trust, Hon. Senior Lecturer, Liverpool School of Tropical Medicine & Member of the CHM Covid-19 Vaccine Expert Working Group
Professor Helen J Lachmann MA MB BChir MD FRCP FRCPath Professor of Medicine & Honorary Consultant Nephrologist Clinical Director UCL Division of Medicine & Clinical Lead for National Amyloidosis Centre, University College London & Royal Free Hospital London NHS Foundation Trust & Vice-chair of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Professor Paul J Lehner PhD FRCP FMedSci Professor of Immunology and Medicine, Wellcome Trust Principal Research Fellow Honorary Consultant Infectious Diseases, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus
Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPath Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals & Member of the Commission on Human Medicines (CHM) & Chair of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA ,FRSC, MBPharmacolSoc Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire
Dr Andrew Riordan MD FRCPCH DTM&H Consultant in Paediatric Infectious Diseases and Immunology, Honorary Clinical Lecturer, University of Liverpool, Alder Hey Children’s NHS Foundation Trust, Liverpool
Professor Chris Robertson PhD MSc BSc Professor of Public Health Epidemiology, University of Strathclyde
Professor Tom Solomon FRCP PhD Chair, Neurological Science and Director, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Hon Consultant Neurologist, Walton Centre NHS Foundation Trust
Dr Robin Thorpe BSc PhD FRCPath Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Mrs Madeleine Wang BA (Hons) Lay Member & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Professor Christopher Weir BSc MSc PhD FRSS Cstat Professor of Medical Statistics & Clinical Trials, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh & Member of Commission on Human Medicines (CHM) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Invited Members of The Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBV EAG)
Professor B Kevin Park BSc, PhD, Hon FRCP, FMedSci, FBTS, HonFBPhS Professor of Pharmacology, Department of Pharmacology, University of Liverpool
Professor Marc Turner MBBS PhD MBA FRCP FRCPath FHEA Professor of Cellular Therapy; Medical Director Scottish National Blood Transfusion Service (SNBTS)
Invited Members of The Chemistry, Pharmacy and Standards Expert Advisory Group (CPS EAG)
Professor Kevin M G Taylor BPharm PhD FRPharmS (Chair) Chair of the British Pharmacopoeia Commission and Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Mr V’Iain G Fenton-May BPharm MIPharm FRPharmS Pharmaceutical Microbiologist
Mr Robert Lowe BPharm FRPharmS Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Dr Susannah Walsh BSc PhD MBA Associate Head, Leicester School of Pharmacy, Associate Professor in Microbiology De Montfort University
Observer
Professor Stuart Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon) Professor of Rheumatology, University of Edinburgh, Western General Hospital, Edinburgh
Invited Experts (participation at specific meetings only)
Professor Ian J Douglas BSc MSc PhD Senior Lecturer in Pharmacoepidemiology, London School of Hygiene & Tropical Medicine & Member of the Pharmacovigilance Expert Advisory Group (PEAG)
Professor Paul-Henri Lambert MD Senior Adviser, Centre of Vaccinology, University of Geneva, Department of Pathology and Immunology, CMU
Professor Linda Sharples PhD Professor of Medical Statistics, London School of Hygiene & Tropical Medicine (LSHTM) and Faculty of Epidemiology and Population Health